Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real‐life setting: the PROSISA Study
Authors:
- Manuela CasulaMCManuela Casula
- Marta GazzottiMGMarta Gazzotti
- Maurizio AvernaMAMaurizio Averna
- Alberto ZambonAZAlberto Zambon
- Alberico L. CatapanoAlberico L. Catapano
- the PROSISA Study GroupTGthe PROSISA Study Group
Open Access
- 1 December 2020
- journal article
- research article
- Published by Wiley in Journal of Internal Medicine
- Vol. 290 (1) , 116-128
Abstract
Aim: Statin‐associated muscle symptoms (SAMS) are a major determinant of poor treatment adherence and/or discontinuation, but a definitive diagnosis of SAMS is challenging. The PROSISA study was an observational retrospective study aimed to assess the prevalence of reported SAMS in a cohort of dyslipidaemic patients.Methods: Demographic/anamnestic data, biochemical values and occurrence of SAMS were collected by 23 Italian Lipid Clinics. Adjusted logistic regression was performed to estimate odds ratio (OR) and 95% confidence intervals for association between probability of reporting SAMS and several factors.Results: Analyses were carried out on 16 717 statin‐treated patients (mean ± SD, age 60.5 ± 12.0 years; 52.1% men). During statin therapy, 9.6% (N = 1599) of patients reported SAMS. Women and physically active subjects were more likely to report SAMS (OR 1.23 [1.10–1.37] and OR 1.35 [1.14–1.60], respectively), whist age ≥ 65 (OR 0.79 [0.70–0.89]), presence of type 2 diabetes mellitus (OR 0.62 [0.51–0.74]), use of concomitant nonstatin lipid‐lowering drugs (OR 0.87 [0.76–0.99]), use of high‐intensity statins (OR 0.79 [0.69–0.90]) and use of potential interacting drugs (OR 0.63 [0.48–0.84]) were associated with lower probability of reporting SAMS. Amongst patients reporting SAMS, 82.2% underwent dechallenge (treatment interruption) and/or rechallenge (change or restart of statin therapy), with reappearance of muscular symptoms in 38.4% (3.01% of the whole cohort).Conclusions: The reported prevalence of SAMS was 9.6% of the whole PROSISA cohort, but only a third of patients still reported SAMS after dechallenge/rechallenge. These results emphasize the need for a better management of SAMS to implement a more accurate diagnosis and treatment re‐evaluation.Keywords
This publication has 34 references indexed in Scilit:
- Understanding patients’ perspective of statin therapy: can we design a better approach to the management of dyslipidaemia? A literature reviewSingapore Medical Journal, 2014
- Phenotype Standardization for Statin-Induced MyotoxicityClinical Pharmacology & Therapeutics, 2014
- N-of-1 (Single-Patient) Trials for Statin-Related MyalgiaAnnals of Internal Medicine, 2014
- Predictors of statin adherence, switching, and discontinuation in the USAGE survey: Understanding the use of statins in America and gaps in patient educationJournal of Clinical Lipidology, 2013
- Discontinuation of Statins in Routine Care SettingsAnnals of Internal Medicine, 2013
- Prevalence and risk factors of muscle complications secondary to statinsMuscle & Nerve, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Statin use and its association with musculoskeletal symptoms--a cross-sectional study in primary care settingsFamily Practice, 2009
- Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO StudyCardiovascular Drugs and Therapy, 2005
- Skin denervation in type 2 diabetes: correlations with diabetic duration and functional impairmentsBrain, 2004